Skip to Content
Morningstar
Get 14 Days Free

Thermo Fisher Scientific Inc TMO

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Thermo Fisher Scientific Delivers Yet Another Strong, COVID-19-Backed Quarter

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

We anticipate a moderate increase to our fair value estimate of wide-moat Thermo Fisher Scientific as we update our model following the release of second-quarter results. Total revenue grew 34% year over year for the quarter to $9.27 billion, marking the fourth consecutive quarter of over 30% growth year over year. Revenue continues to be inflated due to the COVID-19 pandemic response, which accounted for $1.9 billion of total revenue. With the second quarter providing a strong close for the first half of the year, management is raising revenue and adjusted earnings per share guidance for fiscal 2021 to $35.90 billion and $22.07, respectively.

Read Full Analysis

Company Profile

Business Description

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (17%); life science solutions (38%); and lab products and services (38%).

Contact
168 Third Avenue
Waltham, MA, 02451
T +1 781 622-1000
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Aggressive Growth
Employees 75,000

Related

Our Picks
10 Undervalued Wide-Moat Stocks
These are the cheapest names in the Morningstar Wide Moat Focus Index--plus stocks the index has recently added and dropped.
Susan Dziubinski
Market Update
The Winners of the New Definition of Infrastructure
Depending on which broader infrastructure projects take shape, numerous companies could see increased demand.
David Sekera
Investing Specialists
Our Ultimate Stock-Pickers' Top 10 Buys and Sells
Funds focus purchases in basic materials and consumer sectors.
Nupur Balain
Stock Strategist Industry Reports
Coronavirus Vaccine Progress Accelerates
Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.
Karen Andersen
Investing Specialists
Our Ultimate Stock-Pickers' Top 10 Buys and Sells
Stock-pickers find value in times of volatility and continue to purchase and hold high-quality names.
The Morningstar Ultimate Stock-Pickers Team
Premium Article
Stocks for the Next Decade
The future's bright for these 29 companies. Grab the shades.
Susan Dziubinski
Stock Strategist
Leader in Genomic Sequencing Illuminates the Way
Continued technology advancements and market expansion support Illumina's narrow moat.
Michael Waterhouse
Investing Specialists
Top 10 Buys and Sells by the Ultimate Stock-Pickers
A group of top managers continue to keep looking for good investment opportunities, while taking full advantage of a rising (and potentially overvalued) market to book some gains.
The Morningstar Ultimate Stock-Pickers Team
Fund Spy: Morningstar Medalist Edition
Announcing the Morningstar Fund Managers of the Year for 2013
Remarkable performances amid a remarkable year.
Michael Herbst
Credit Insights
Payrolls Not Too Hot, Not Too Cold
It appears that the corporate-bond market believes Friday's jobs report was high enough to suggest an advancing economy, but not so strong as to prompt a Fed taper.
David Sekera
Our Picks
Stuck in the Middle Not a Bad Place to Be With These Funds
A handful of analyst-recommended moderate-allocation funds have proved their mettle in good times and bad.
Adam Zoll
Credit Insights
Credit Spreads Remain Range-Bound
We are seeing an increase in idiosyncratic catalysts that are specific to an individual issuer as opposed to industry factors that affect an entire sector.
David Sekera
Quarter-End Insights
Our Outlook for the Credit Markets
Widening investment-grade credit spreads and rising interest rates lead to losses.
David Sekera
US Videos
Stocks Attractive on a Relative, But Not Absolute, Basis
Investors should keep their expectations in check with few asset classes looking particularly attractive and complacency in the marketplace, says Allocation Fund Manager of the Year David Giroux of T. Rowe Price Capital Appreciation.
Greg Carlson
Fund Spy
Announcing Morningstar's Fund Managers of the Year for 2012
These skippers shone amid a challenging market environment.
Michael Herbst
US Videos
Are Equity Fair Values Teetering on the 'Cliff'?
A lot of companies are very well positioned regardless of how the fiscal cliff gets resolved, as long as it gets resolved, says Morningstar's Heather Brilliant.
Jeremy Glaser
Fund Spy
Our 5 Nominees for Allocation Fund Manager of the Year
Success in 2012 took many forms.
Laura Pavlenko Lutton
Quarter-End Insights
Our Outlook for Health-Care Stocks
Election and potential sequestration emerge as key topics for health care.
Alex Morozov
Investing Specialists
Our Ultimate Stock-Pickers' Top 10 Buys and Sells
The decline in the equity markets created plenty of buying opportunities in the most recent period, but some of our managers seem to have jumped into energy stocks sooner than they should have.
The Morningstar Ultimate Stock-Pickers Team
US Videos
Will Life Sciences Firms Fall Off the Fiscal Cliff?
Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.
Jeremy Glaser